Follow Us:
Nirsevimab Exporter From India

Nirsevimab

Nirsevimab is a long-acting monoclonal antibody used to prevent respiratory syncytial virus (RSV)-associated lower respiratory tract disease in newborns and infants during their first RSV season, and in selected high-risk children entering a second season, depending on local recommendations. It works by binding to the RSV fusion (F) protein, preventing the virus from entering respiratory cells and reducing the risk of severe infection. Nirsevimab is supplied as a ready-to-use solution for intramuscular injection, with the dose determined by the child’s body weight and age. Common side effects include injection-site reactions, rash, and fever. Serious hypersensitivity reactions, including anaphylaxis, are uncommon but may occur. Administration should follow local immunisation guidance and be supervised by a qualified healthcare professional, with particular precautions for children with a history of severe allergic reactions to its ingredients.

  • Dosage Form:
  • Dosage Strength:
  • Manufacturer:
  • CAS No.:
  • Status:

Applications of Nirsevimab

Nirsevimab was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

is okay

Contraindication of Nirsevimab

Availability of Nirsevimab

Delivery of Nirsevimab

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Nirsevimab.

The is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Nirsevimab.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Nirsevimab, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Nirsevimab Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Nirsevimab

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Nirsevimab Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Nirsevimab, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Nirsevimab

The export of Nirsevimab from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Nirsevimab Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Nirsevimab specifications, certificates of analysis, and other supporting documents required for Nirsevimab export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Nirsevimab export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Nirsevimab regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Nirsevimab documentation, labelling, Nirsevimab manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Nirsevimab Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Nirsevimab, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.

Email Us

info@primeerahealthcare.com

Call Us

+(123) 456 789 00

Follow Us

Primeera Healthcare

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.